Norway-based medical diagnostics company Gentian Diagnostics AS (Euronext Growth Oslo:GENT) said on Friday that its SARS-CoV-2 antibody test is moving to the next development phase.
The project has progressed from the proof-of-concept phase to the project initiation and optimisation phase. Gentian has established an official project plan with an approved budget and a dedicated project team, and the timeline to launch is set for the fourth quarter of 2021.
Gentian's SARS-CoV-2 antibody test is designed to offer the first assay on high-throughput open-access clinical chemistry platforms, supporting COVID-19 vaccination efforts and aiding in community management by the determination of immunisation status.
Lilly presents Phase 3b Taltz (ixekizumab) plus Zepbound (tirzepatide) data at AAD Annual Meeting
Novartis to acquire Excellergy in USD2bn deal
AstraZeneca's tozorakimab meets primary endpoints in two Phase III COPD trials
Pharming receives positive CHMP opinion for Joenja marketing authorisation
Biocytogen partner NEOK Bio secures FDA IND clearance for cancer therapy candidate
Hoth Therapeutics deploys OpenClaw AI platform for drug discovery
Insilico Medicine and Tenacia expand AI-driven R&D collaboration
Eisai and Nuvation Bio report taletrectinib MAA validated by European regulator
Novo Nordisk's Awiqli once-weekly basal insulin treatment approved by US FDA